Peter Rossing: Clinical Trials

8 trials sponsored by Peter Rossing, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 recruiting. 5 Phase 4, 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 45Completed 4, Recruiting 1
Phase 22Completed 1, Recruiting 1
Phase 31Completed 1

Follow Peter Rossing: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
Dapagliflozin, Semaglutide, Finerenone - Chronic Kidney Disease(CKD)
Phase 4RecruitingPeter Rossing1252025-06-202025-11-20
Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
Kerendia (Finerenone, BAY94-8862), Placebo - Cardiovascular Autonomic Neuropathy, Type 2 Diabetes
Phase 2RecruitingPeter Rossing1002025-05-022025-05-25
PeRsOnalising Treatment Of Diabetic Nephropathy:
Diabetes Mellitus, Type 1, Diabetes Complications
CompletedPeter Rossing2102016-04-012018-04-26
Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes
Dapagliflozine 10 mg once daily tablet treatment, Placebo identical once daily tablet treatment - Type 2 Diabetes, Diabetic Nephropathy
Phase 4CompletedPeter Rossing402015-08-012018-09-10
Microalbuminuria and Allopurinol in Type 1 Diabetes
Allopurinol, Placebo - Type 1 Diabetes, Diabetic Nephropathy
Phase 4CompletedPeter Rossing302014-09-012018-09-10
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
Spironolactone, Placebo, Standard care - Diabetic Nephropathy, Diabetic Retinopathy
Phase 2 / Phase 3CompletedPeter Rossing17772014-03-012018-12-21
Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes
liraglutide - Type 2 Diabetes
Phase 4CompletedPeter Rossing322012-08-012015-02-02
Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy
Paricalcitol - Cardiovascular Disease, Diabetic Nephropathy
Phase 4CompletedPeter Rossing482010-04-012012-04-13

Conditions studied

Diabetic Nephropathies (5)  ·  Diabetes Mellitus, Type 2 (3)  ·  Albuminuria (2)  ·  Diabetes Mellitus, Type 1 (2)  ·  Renal Insufficiency, Chronic (2)  ·  Cardiovascular Diseases (1)  ·  Diabetes Complications (1)  ·  Diabetes Mellitus (1)  ·  Diabetic Neuropathies (1)  ·  Diabetic Retinopathy (1)  ·  Hypertension (1)

Interventions

finerenone (2)  ·  Allopurinol (1)  ·  Liraglutide (1)  ·  Spironolactone (1)  ·  Standard of Care (1)  ·  dapagliflozin (1)  ·  paricalcitol (1)  ·  semaglutide (1)

Countries

Denmark (8)  ·  Germany (2)  ·  Spain (2)  ·  Belgium (1)  ·  Czechia (1)  ·  Greece (1)  ·  Italy (1)  ·  Netherlands (1)  ·  North Macedonia (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Adriaan Kooy, MD (1)  ·  Alberto Ortiz, MD (1)  ·  Andreas Birkenfeld, MD (1)  ·  Christian Delles, MD (1)  ·  Gerjan Navis, MD (1)  ·  Goce Spasovski, MD (1)  ·  Ivan Rychlik, MD (1)  ·  Joachim Beige, MD (1)  ·  Joline Beulens, MD (1)  ·  Lise Tarnow, MD (1)  ·  Marina Noutsou, MD (1)  ·  Marjin Speeckaert, MD (1)  ·  Matias Trillini, MD (1)  ·  Peter Girman, MD (1)

Results publications

PMID 25935863, PMID 26936907, PMID 29781558, PMID 32135136, PMID 32340841, PMID 33107592, PMID 35998283, PMID 36841085, PMID 37171199, PMID 38449081, PMID 39434255, PMID 41130701

NIH funding

2009 (1), 2015 (1), 2023 (1)